title: KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.
abstract: Killer immunoglobulin-like receptors (KIRs) on natural killer cells (NKs) recognize groups of human leukocyte antigen (HLA) class I alleles. Cells without an inhibitory HLA ligand may trigger NK activation. Reduced risk of relapse has been reported in malignant hematologic diseases after haploidentical transplantation when HLA ligands against the inhibitory KIRs present in the donor were absent in the recipient. We performed haploidentical transplant in three children with refractory solid tumors. Our results showed that beneficial antitumor effects could be observed in the presence of inhibitory KIR-HLA mismatch. These preliminary results suggest a possible association between disease control and NK cell alloreactivity.
authors.affiliation: Department of Pediatric Hematology and Oncology, Hospital Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain. aperezm.hnjs@salud.madrid.org
authors.forename: Antonio
authors.initials: A
authors.lastname: Pérez-Martínez
authors.forename: Wing
authors.initials: W
authors.lastname: Leung
authors.forename: Evangelina
authors.initials: E
authors.lastname: Muñoz
authors.forename: Rekha
authors.initials: R
authors.lastname: Iyengar
authors.forename: Manuel
authors.initials: M
authors.lastname: Ramírez
authors.forename: José Luis
authors.initials: JL
authors.lastname: Vicario
authors.forename: Alvaro
authors.initials: A
authors.lastname: Lassaletta
authors.forename: Julián
authors.initials: J
authors.lastname: Sevilla
authors.forename: Marta
authors.initials: M
authors.lastname: González-Vicent
authors.forename: Luis
authors.initials: L
authors.lastname: Madero
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Díaz-Pérez
mesh_terms: D000293:Adolescent; D001859:Bone Neoplasms / Q000235:genetics / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D002675:Child, Preschool; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D015235:HLA-B Antigens / Q000235:genetics; D015236:HLA-C Antigens / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000637:transplantation; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary; D008297:Male; D009447:Neuroblastoma / Q000235:genetics / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D054340:Receptors, KIR / Q000235:genetics*; D012074:Remission Induction; D012208:Rhabdomyosarcoma / Q000235:genetics / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D012512:Sarcoma, Ewing / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D013736:Testicular Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy
chemical_list: D015235:HLA-B Antigens; D015236:HLA-C Antigens; D054340:Receptors, KIR